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Abstract 
As proton therapy increases in popularity, so does the need for effective quality assurance. 
Proton therapy institutions participating in NCI funded clinical trials rely heavily on the 
credentialing and auditing services of IROC-H and therefore the process must be well 
understood. The purpose of this project is to understand the uncertainties in proton therapy 
treatment planning for the IROC-H proton phantom QA program due to variations in CT 
technique and proton energy. It was hypothesized that variations in CT technique and proton 
energy will alter the delivered dose distributions of typical proton treatments by reducing the 
percent of passing pixels by 10% using a gamma analysis criteria of ±3%/5mm as measured 
using a heterogeneous proton QA phantom. A CT phantom used by IROC-H during therapy site 
visits was scanned using three CT techniques (80, 120, 140kV) with a CT scanner used for 
proton therapy simulations and irradiated with a passively scattered beam at three energies 
(140, 200, 250 MeV) to measure, respectively, HU and Relative Linear Stopping Power (RLSP) in 
order to create HU to RLSP calibration curves for comparison with reference curves as defined 
by this study. The phantom has proton equivalent materials with a wide variety of HU and 
RLSPs to allow for the creation of a calibration curve for common tissue equivalent materials. 
Treatment plans were created for an anthropomorphic proton lung phantom using the various 
CT technique/ beam energy calibration curves to determine the differences in the dose 
distributions by performing a gamma analysis. The 3D gamma analysis resulted in a pass rate of 
100% for all plans and the 2D gamma analysis resulted in a pass rate above 99%. This result 
implied the varying treatment plans did not substantially affect the outcome of the dose 
comparison and therefore rejects the stated hypothesis and further work is needed to 
investigate the uncertainty present in this QA process. 
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Chapter 1 
1 Introduction and Background 
1.1 Statement of Problem 
1.1.1 General Problem Area 
Proton and radiation therapy is continuing to grow as a radiation oncology treatment modality, 
being adopted by an increasing number of institutions in the United States and around the 
world. There are currently 17 clinically active proton centers in the United States with another 
14 under construction and an additional 3 centers still in the planning stages [1][2][3]. As the 
number of proton therapy facilities grows, so does the number of facilities seeking to 
participate in the National Cancer Institute’s (NCI) funded proton therapy clinical trials and the 
number of patients impacted by these proton trials. The NCI, in 2014, implemented the 
National Clinical Trials Network (NCTN), a network of five clinical trial groups conducting multi-
institutional phase I, II and III clinical trials with the goal of developing new protocols, 
conducting the trials and compiling data from many institutions in order to improve the 
standard of care for the treatment of cancer [4]. As a part of the NCTN, the NCI funded a central 
Core group to a provide quality assurance and data management service to the NCTN and their 
participants. This Core group is the Imaging and Radiation Oncology Core (IROC) Cooperative. 
IROC consists of 6 different radiotherapy and imaging QA centers located across the USA. One 
of the QA centers is the Imaging and Radiation Oncology Core Houston (IROC-H) QA Center, 
formerly known as the Radiological Physics Center (RPC). The mission of IROC-H is to ensure 
consistent and comparable radiation doses are delivered by the participating institutions and 
that the highest quality data is included in NCTN radiation therapy clinical trials. To accomplish 
its mission, IROC-H performs dosimetry audits of institutions participating in NCI funded clinical 
trials with a combination of off-site mail-in thermoluminescent dosimeter (TLD) and optically 
stimulated luminescent dosimeter programs, on-site dosimetry review visits, retrospective 
inspection of patient records, and trial credentialing activities that include end-to-end (E2E) 
anthropomorphic phantom irradiations [5]. These dosimetry audits are performed for both 
photon and proton radiotherapy facilities. Currently, IROC-H currently monitors 2040 
institutions worldwide of which 17 are institutions utilizing proton therapy [5].  
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The anthropomorphic phantoms used by IROC-H include phantoms designed for photon and 
proton therapy. The phantoms cover various anatomical sites such as the head, head & neck, 
thorax, spine, abdomen and pelvis [5]. In 2014, 627 phantoms were shipped from IROC-H to 
institutions all over the world. These phantoms are used for the purpose of credentialing an 
institution’s ability to use advanced radiotherapy technologies in the NCTN clinical trial setting. 
Phantoms are constructed to be anatomically similar to humans, have targets and organs at 
risk, have plastics that are good tissue substitutes and contain radiation dosimeters (TLD and 
radiochromic film). Institutions are asked to treat the phantom as if it were a patient and to 
complete the end-to-end treatment process from imaging, to treatment planning, to patient 
setup, and finally treatment delivery.  The phantom is then sent back to IROC-H for the 
evaluation of the dosimeters.   
A key component of the treatment process is the imaging phase. In both photon and proton 
therapy computed tomography (CT) imaging is used for simulating and planning the radiation 
treatment. CT enables the physician and dosimetrist to visualize targets, organs at risk and 
tissue heterogeneities so that a conformal treatment plan may be designed. Each treatment 
planning system used by an institution has a built-in calibration curve used to convert the 
Hounsfield units (HU) of the CT to electron density for photon treatment dose calculations or to 
relative linear stopping power (RLSP) for proton treatment range definition. These calibration 
curves are essential for accurate dose distribution calculations. Any uncertainty in the 
calibration curves may ultimately lead to variability in the dose delivery to a patient or one of 
IROC-H’s QA phantoms. An example of a proton CT calibration curve can be seen in the curve 
used clinically at MD Anderson’s PTC-H shown below in Figure 1.   
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Figure 1. Proton CT Calibration curve used clinically at the PTC-H 
 
1.1.2 Specific Problem 
 
The use of proton therapy in NCI clinical trials requires that a proton facility first be approved by 
IROC-H and then it may have to complete additional credentialing requirements depending on 
the specific clinical trial. Both of these phases include the irradiation of IROC-H’s E2E proton QA 
phantoms, specifically designed for use with proton therapy, to assess the facility’s ability to 
deliver accurate doses to the desired location.  
 
Proton E2E QA phantoms are designed with materials that have an HU value and RLSP that fall  
on the proton calibration curve used by proton planning systems to convert HU to RLSP. A 
phantom made of such materials is termed “proton equivalent.” A phantom is designated as 
proton equivalent when it has an RLSP within five percent of the tissue-equivalent calibration 
curve [6]. These phantoms are designed by IROC-H and the materials are tested extensively to 
determine proton equivalence. It has been determined that phantom materials suitable for use 
in photon beams are not always suitable for use in proton beams. For this reason IROC-H has 
separate phantoms for use with photon and proton therapy quality assurance testing. IROC-H 
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currently has five E2E QA phantoms that can be used for proton therapy: head, spine, thorax, 
liver, and pelvis. All of these phantoms require CT imaging as a part of the E2E audit and any 
variation in the HU assigned to each phantom component could lead to errors in the dose 
calculation by the planning system due to variations in the calibration curve as a function of CT 
technique.  Since the proton calibration curve (HU vs. RLSP) in each planning system is 
determined for a single proton reference energy, changes in proton energy used to deliver 
treatment could also result in dose delivery errors if the RLSP values for the new proton energy 
do not match those used for the calibration curve. Variability in CT technique and proton beam 
energy may play a role in the observed differences in the dose and dose distributions measured 
by IROC-H’s QA phantoms as compared to the planning system calculations.   
 
IROC-H monitors 17 institutions using proton therapy and has observed a lower phantom pass 
rate for proton institutions. This low proton pass rate has raised red flags in the proton 
phantom quality assurance program. The participating proton institutions receive an initial site 
visit by IROC-H physicists during which their calibration curve or curves are inspected. It has 
been discovered that most institutions use a single calibration curve with a minority using two 
curves, but no institutions uses more than two. IROC-H believes that a proton institutions’ use 
of a single reference calibration curve, created with the parameters of a single CT technique 
used to determine HU and a single proton energy used to determine RLSP, may be a source of 
uncertainty in the E2E quality assurance process that contributes to institutional phantom 
failures. Uncertainty arises when the parameters under which the calibration curve was created 
are not the same parameters as those that are used to image and irradiate the phantom 
according to IROC-H’s quality assurance protocols. Moyers’ work on this subject supports the 
claim that changes in the calibration curve can impact dose delivery [7].  
 
This project will focus on the uncertainty in the proton calibration curve due to CT technique 
and proton energy and how this uncertainty may translate to distributions in dose.  
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1.1.3 Importance of Topic 
 
Clinical trials are research studies involving the direct treatment of patients to test a therapy 
before it becomes standard practice in the clinic. Thousands of patients are treated each year 
under clinical trials and provide data to determine the effectiveness of various cancer 
treatment approaches. New technology and methods would not be able to be utilized without 
first being subject to clinical trial research. In this way clinical trials are vital to moving forward 
in the successful detection and treatment of cancer.  
 
In 2014, over 19,000 patients participated in NCI clinical trials conducted by 14,000 
investigators at 3,100 different institutions [8]. This massive aggregate of data is only useful if 
the programs and protocols deliver treatment accurately and consistently. A large portion of 
these trials involve radiation therapy and must be monitored regularly to maintain the 
necessary quality of data to be used in cooperative clinical trial studies. IROC is instrumental in 
credentialing and monitoring these institutions and makes it possible for trials to successfully 
accomplish their goals.  
 
The goal of this study is to better understand the uncertainty in the measures used by IROC-H 
for determining the quality of an institution’s proton therapy delivery. A better understanding 
of this uncertainty will result in a higher level of confidence for the use of the phantom services 
for proton QA. This study is focusing on the uncertainty associated with the calibration curve 
used by the treatment planning system to convert CT number, or HU, of the images used for 
planning to the RLSP of protons to determine the desired energy to be deposited by the 
protons in a particular tissue.  
 
As previously discussed, many proton institutions monitored by IROC are using a single 
calibration curve regardless of simulation and treatment parameters. The use of a single curve 
has the potential to cause errors in dose distribution during an IROC-H phantom irradiation if 
the parameters used are not those that were used to develop the calibration curve. This 
discrepancy could lead to a material being shifted on the calibration curve, which could cause 
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the treatment planning system to incorrectly calculate the range of the protons and dose to be 
delivered to a particular material in the phantom.  
 
In addition to monitoring clinical trial participants and their ability to provide correct trial data, 
IROC-H has also been successful at detecting and preventing radiation incidents [9][10], thus 
playing a role in patient safety. Proton therapy utilizes the Bragg peak behavior of protons in 
which a very large percentage of energy is deposited at the distal end of the proton’s path. Due 
to these high doses and steep dose gradients involved in proton therapy, accidents have the 
potential to cause more harm to patients than photon therapy, furthering the need for 
independent quality assurance checks by institutions such as IROC-H and their QA phantoms. 
This safety aspect enhances the incentive to reduce the uncertainty in IROC-H’s proton 
phantom program. 
 
1.2 Hypothesis 
 
The hypothesis of this project is as follows:  
 
Variations in CT technique and proton energy will alter the delivered dose 
distributions of typical proton treatments by reducing the percent of passing pixels 
by 10% using a gamma analysis criteria of ±3%/5 mm as measured using a 
heterogeneous proton QA phantom.  
 
The specific aims to test this hypothesis are: 
 
1. Measure the RLSP of designated materials and create custom HU vs. proton RLSP curves 
for 3 commonly used CT techniques and 3 proton energies. 
2. Create a treatment plan for a heterogeneous proton QA phantom with a standard 
treatment planning system HU vs. RLSP calibration curve. Then create nine treatment 
plans for the same QA phantom using the three CT image datasets. 
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3. Incorporate custom proton energy dependent calibration curves determined in Aim 1 
into the treatment planning system and estimate the change in dose coverage due to a 
change in proton energy. Analyze the plan differences with a gamma analysis. 
 
1.3 Literature Review 
1.3.1 Proton background 
1.3.1.1 History 
 
The discovery of the proton is credited to Ernest Rutherford for his published experiments in 
1919 in changing one element to another titled “Collision of Alpha Particles with Light Atoms” 
in which he identified a hydrogen nucleus [11]. Protons have since been discovered to be 
particles in the nucleus of every atom with a positive charge of 1.602 *10-19 Coulombs and a 
mass of 1.673*10e-27 kg.  
 
The use of protons for therapeutic purposes was first proposed by Robert Wilson in 1946 in his 
paper “Radiological Use of Fast Protons” [12]. He suggested that the new technology that 
allowed for the acceleration of protons to higher energies enabled charged particles to 
penetrate bodies for medical uses.  
 
From the early 1950’s to 1990 proton therapy began to grow as an idea for therapy and 
patients began to be treated at physics laboratories around the world [13]. In 1990, the nation’s 
first hospital-based accelerator used for proton therapy opened at Loma Linda University 
Medical Center [14][15]. The field has continued to grow in the years since and there are now 
17 proton therapy facilities in operation throughout the United States having treated over fifty 
thousand patients [1].   
 
M.D. Anderson Cancer Center’s (MDACC) proton therapy center - Houston (PTC-H) became 
clinically active in 2006 and has three rotating gantries, two providing passive scattering beams 
and one providing a pencil beam scanning option, and a fourth treatment room with two fixed 
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beamlines [16]. The center has the capability of treating patients with energies up to 250 MeV. 
This project was completed at the MDACC PTC-H. 
 
1.3.1.2 Proton behavior 
 
Protons are valuable for therapeutic use because of their unique behavior in tissue. Protons can 
interact via coulomb, elastic, or inelastic interactions. Protons primarily lose energy via coulomb 
interactions with the outer electrons of target atoms. This loss of energy is described by the 
continuous slowing down approximation (CSDA). As a proton interacts with particles it loses 
energy as a first approximation to the inverse of the proton’s velocity squared. As the proton 
slows down more and more, this causes the majority of a proton’s energy to be deposited at 
the distal end of its range. The mass stopping power is described by the Bethe Bloch equation 
which is approximated below [17].  
 
𝑆(𝐸)
𝜌
=
4𝜋𝑟𝑒
2𝑚𝑐2
𝛽2
1
𝑢
𝑍𝑧2𝐿(𝛽)
𝐴
  ( Equation  1 ) 
 
In this formula, the following variables are defined: 
S(E) Linear stopping power 
re Radius of an electron 
m Mass of an electron 
c Speed of light 
β Particle velocity/ speed of light 
u Atomic mass unit 
Z Atomic number 
z Charge of a proton 
L(β) Stopping power 
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The large characteristic deposition of energy at the end of the range of a monoenergetic proton 
beam is called a Bragg peak after William Henry Bragg who discovered it in 1903 [18]. Bragg 
peaks can be used to deposit a large dose in a tumor while sparing surrounding tissue because 
of the steep falloff of the dose gradient. The range of the protons and therefore the depth of 
energy deposition can be manipulated by changing the energy of the protons to better conform 
to a disease site. 
 
Bragg peaks can be further manipulated with the use of a spread out Bragg peak (SOBP) to 
deliver a uniform dose over a specified distance. A range modulation wheel as pictured in 
Figure 2 is used to create this plateau of dose at the desired depth. A range modulation wheel is 
made of steps of varying absorber thickness to alter the range and intensity of protons passing 
through as the RMW rotates rapidly. This has the effect of creating many Bragg peaks that are 
superimposed to create a uniform dose across the tumor.  
 
 
Figure 2. Range Modulation Wheels used at PTC-H [17] 
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A comparison of proton and photon depth dose profiles reveals the benefits of using protons 
therapeutically and can be visualized through their depth dose curves shown in Figure 3. Two 
apparent advantages of the proton profile are the uniform maximum dose and the steep dose 
falloff at the distal end of the range. While this steep gradient provides the advantage of 
sparing normal tissue, it also requires very precise localization of the SOBP so as to not deliver a 
very high dose to the normal tissue. Contrastingly, photons have a maximum dose at a shallow 
depth and a decreasing but relatively high distal dose.  
 
 
Figure 3. Depth Dose Comparison of Proton and Photon Therapy [19] 
 
1.3.1.3 Radiobiology 
 
Protons and other heavy ions have the advantage of having a relative biological effectiveness 
(RBE) greater than that for photons. RBE is defined in Equation 2.  
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𝑅𝐵𝐸 =
𝐷𝑜𝑠𝑒 𝑜𝑓 𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑒 𝑟𝑎𝑑𝑖𝑎𝑡𝑖𝑜𝑛 𝑡𝑜 𝑝𝑟𝑜𝑑𝑢𝑐𝑒 𝑎𝑛 𝑒𝑓𝑓𝑒𝑐𝑡
𝐷𝑜𝑠𝑒 𝑜𝑓 𝑡𝑒𝑠𝑡 𝑟𝑎𝑑𝑖𝑎𝑡𝑖𝑜𝑛 𝑡𝑜 𝑝𝑟𝑜𝑑𝑢𝑐𝑒 𝑎𝑛 𝑒𝑓𝑓𝑒𝑐𝑡
  ( Equation  2 ) 
 
The reference dose is generally defined to be 60Co and protons are clinically defined to have an 
RBE of 1.1, compared to an RBE of 1.0 for photons and electrons. This implies that for the same 
biological effect, 10% less physical dose will be needed with protons than with photons or 
electrons. For this reason proton dose is often expressed in terms of Cobalt Gray Equivalent 
(CGE) which is defined in Equation 3. 
 
𝐶𝐺𝐸 = 𝐷𝑜𝑠𝑒𝑝𝑟𝑜𝑡𝑜𝑛𝑠 ∗ 1.1  ( Equation  3 ) 
 
In Equation 3, Doseprotons is the physical dose of the protons.  
 
1.3.2 Proton beam 
 
The PTC-H has the capability of producing both passively scattered and pencil beam spot 
scanning proton beams. This project focuses on passive scattering. PTC-H uses the double 
scatter technique to create the passive scatter beam using a series of nozzle components that 
include a first scatterer, a RMW, a second scatterer, a range shifter, an aperture, and a 
compensator as shown in Figure 4. All of these components may be altered to modify the 
beam. The first scatterer serves to spread the beam laterally while the second scatterer serves 
to flatten the beam, creating a uniform energy across the entire beam [20]. A rendering of the 
nozzle can be seen below. 
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Figure 4. Passive scatter nozzle from PTC-H [16] 
 
To be therapeutically useful, protons must be accelerated to very high energies with a 
cyclotron, synchrotron, or synchrocyclotron. The PTC-H uses a synchrotron system. This consists 
of a linac injector that generates the proton beam and accelerates it to be funneled into the 
synchrotron ring where it is further accelerated to the desired energy then extracted to be used 
in an individual gantry for a patient [16]. 
 
Pencil beam scanning, though a growing area of proton therapy, is not utilized in this project 
and will not be discussed here.  
 
1.3.3 CT calibration 
 
Proton therapy is able to effectively treat conformal tissues because of the use of computed 
tomography (CT) imaging. CT images serve as the input to treatment planning systems that 
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enable the creation of a conformal plan to treat the tumor and spare normal tissue by 
accounting for these heterogeneities.  
 
The process of patient treatment of an IROC-H phantom audit begins with CT simulation in 
which the patient or phantom is imaged with CT to be used for planning on. These images are 
imported into the facility’s treatment planning system at which point the system uses a 
predefined calibration curve to convert HU, the data from the CT image, to RLSP, the energy to 
be deposited by the protons. This calibration can be determined in one of two ways, with the 
stoichiometric method, or with the tissue substitution method.  
 
The CT number, or HU, is defined in Equation 4.  
 
𝐻𝑈 = 1000 ∗
µ𝑚𝑎𝑡𝑒𝑟𝑖𝑎𝑙−µ𝑤𝑎𝑡𝑒𝑟
µ𝑤𝑎𝑡𝑒𝑟
  ( Equation 4 ) 
 
In Equation 4 µmaterial is the linear attenuation coefficient of the material being analyzed and 
µwater is the linear attenuation coefficient of water [7]. HU is a convenient way to quantitatively 
describe how a material attenuates x-rays in a CT image.  
 
The second factor used in the calibration curve is the RLSP of the protons. This is a measure of 
how protons deposit energy in a particular material relative to that of water.  
 
1.3.3.1 Stoichiometric method 
 
Although not used for this project, it is worth noting that the stoichiometric method has been 
shown to be more accurate than the tissue substitution method and is the method used by the 
PTC-H [21][22][23]. The stoichiometric method examines the problem that tissue equivalent 
materials are not always sufficiently close in composition to yield accurate RLSP values for 
patient tissues. This method seeks to correct for the differences in elemental composition 
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between tissue substitutes and real tissues. This is accomplished by parameterizing the HU 
values into a scaled HU with photoelectric, coherent scatter, and incoherent scatter 
components [24]. The dependence of attenuation is fit as a function of atomic number as 
shown in Equation 5. This can be done for any tissue substitute with a known composition and 
density.  
 
𝐻𝑈𝑠𝑐𝑎𝑙𝑒𝑑 = 𝜌𝑒(𝐴𝑍
3.62 + 𝐵𝑍1.86 + 𝐶)   ( Equation 5 ) 
 
In Equation 5 ρe is the electron density, Z is the atomic number, and A is a photoelectric 
component constant, B is a coherent scatter component constant, and C is an incoherent 
scatter component constant.  
 
1.3.3.2 Tissue substitution method 
 
The tissue substitution method is the original method of determining the calibration curve. In 
this method, a variety of materials determined to be tissue equivalent are scanned and 
irradiated to determine their HU and RLSP. This curve can then be imported into the treatment 
planning system to be used to correct for heterogeneities in patient plans. The RLSP is 
calculated using the Bethe-Bloch formula described previously. The Moyers et al. describes the 
creation of a calibration curve with a large number of materials and outlines a simplistic 
alternative for RLSP calculations. Moyers defines the RLSP in Equation 6. 
 
𝑅𝐿𝑆𝑃 =
𝑅90,𝑤𝑎𝑡𝑒𝑟−𝑅90,𝑚𝑎𝑡𝑒𝑟𝑖𝑎𝑙
𝑡𝑚
   ( Equation 6 ) 
 
R90,water is the depth to distal 90% ionization in the water phantom by itself and R90,material is the 
depth to distal 90% ionization in the water phantom with the slab of material in front. tm is the 
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thickness of the slab and must be known very precisely in this calculation to yield accurate 
results [7].  
1.3.4 Gamma Analysis 
 
The comparison of measured and calculated dose distributions is a critical part of 
commissioning and quality assurance on treatment planning systems. Daniel Low developed a 
technique that provides a quantitative measure of this comparison that can be displayed and 
analyzed where this had previously not been possible. He termed this measure the gamma 
index and this method was used in this study to compare dose distributions.  
 
Low’s method uses an elliptical surface to take into account both dose difference and distance 
to agreement (DTA) metrics when comparing distributions. Criteria for both dose difference 
and DTA are inputs into the calculation and determine the size and shape of the ellipsoid used. 
Dose difference is emphasized in regions of uniform dose while DTA is emphasized in regions of 
steep dose gradients. The ellipsoid is centered on a measured point to be tested and if the 
measured value is found on this surface the point is considered “passing” [25][26]. Figure 5 
shown below was developed by Low and gives a geometrical presentation of the dose 
difference and DTA applications independently for both 2D and one dimensional (1D), 
respectively, and Figure 6 is Low’s geometrical presentation of how these metrics work 
together, again in 2D and 1D, respectively.  
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Figure 5. Geometrical representation of dose difference and DTA [20] 
 
 
Figure 6. Geometrical representation of both dose difference and DTA [20] 
 
In these representations, the following variables are used: 
 ΔDM: Dose-difference criterion 
 ΔdM: DTA criterion 
 Dm(rm): Measured dose 
 Dc(rc): Calculated dose 
 δ(rm,rc): Difference between measured and calculated doses 
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The gamma index is quantitatively defined in Equation 7 below. A γ≤1 is considered “passing,” 
while a γ>1 is considered “failing.” 
 
𝛾(𝑟𝑚 , 𝑟𝑐) = √
𝑟2(𝑟𝑚,𝑟𝑐)
𝛥𝑑𝑀
2 +
𝛿2(𝑟𝑚,𝑟𝑐)
𝛥𝐷𝑀
2    ( Equation 7 ) 
 
The method described here was developed to compare two dimensional (2D) measured dose 
distributions to dose distributions calculated by a treatment planning system. IROC-H has a 
need to compare 2D dose distributions from film and three dimensional (3D) dose 
measurements and performs a registration and gamma analysis using an open source program 
called A Computational Environment for Radiotherapy Research (CERR). CERR uses the Matlab 
language and is widely used to share radiotherapy data results in an easily accessible format. 
The goal of this study is to compare 3D dose calculations against other 3D dose calculations 
which has recently been made possible with upgrades in the CERR software to include 3D 
gamma analysis. 
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Chapter 2 
 
2 Materials and Methods  
2.1 Phantoms 
2.1.1 Proton CT Phantom  
The proton CT phantom shown in Figure 7 was created by IROC-H while searching for 
“proton equivalent” materials to be used for QA purposes. All materials in the phantom 
were measured to have RLSP’s within 5% of the proton CT calibration curve used clinically at 
the MD Anderson Proton Center. It contains inserts of materials all measured to be “proton 
equivalent” including water, polyethylene, balsa wood, blue water, PRESAGE®, and 
Techtron® HPV [6]. These materials span a wide range of HU and RLSP’s on the curve and 
are intended to be utilized to create a reasonable fit with only a small number of materials. 
Currently IROC-H end-to-end audit procedures utilize anthropomorphic phantoms with 
materials that are not always “proton equivalent.” This requires institutions to override 
RLSPs for certain materials, which does not allow the accurate assessment of the calibration 
curve and may introduce errors in the dose calculations. The proton CT phantom is 
currently used by IROC-H to verify consistency of calibration curves used by proton facilities 
participating in NCI-funded proton therapy clinical trials.  
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The proton CT phantom was used in this project as the standard for creating calibration 
curves to be used for analyzing the differences in curves with varying proton parameters. 
 
 
Figure 7. Proton CT Phantom 
 
2.1.2 Proton lung phantom 
In 2011 Tony Blatnica modified an existing IROC-H thorax phantom that was used for 
photon stereotactic body radiation therapy (SBRT) to be more “proton equivalent” so 
that it could be sent out to proton institutions for approval/credentialing purposes. The 
need for the modification stemmed from the lack of proton equivalent materials and 
air gaps in the existing dosimetry insert that created difficulties in characterizing the 
insert in a proton beam [27]. Blatnica utilized the existing base phantom and created a 
new dosimetry insert using balsa wood as a verified lung equivalent material to replace 
the cork that was previously being used. In 2013 Jim Neihart developed a new lung 
phantom as shown in Figure 8 that was completely proton equivalent. This new 
HPV PRESAGE® 
Air 
Blue Water Balsa Wood 
Water 
Polyethylene 
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phantom retained the insert designed by Blatnica and received a new phantom base, 
ribs and heart made of materials more suitable for use in a proton beam as well as the 
addition of an intra-fractional respiratory motion simulation capability. 
 
Figure 8. Proton Lung Phantom 
 
The proton lung phantom designed by Neihart pictured above in Figure 8 is currently in 
use by IROC-H for proton quality assurance assessments and is the lung phantom used 
in this project. The phantom is designed to simulate a single lung, deemed sufficient 
due to the fact that most lung tumors are treated with a single lateral field and a single 
oblique or anterior field, thus there was no need to provide a contralateral lung. The 
phantom is comprised of five proton equivalent tissue simulating materials. To simulate 
lung, soft tissue, heart tissue, tumor, and bone, the phantom uses respectively balsa 
wood and cork, solid water, blue water, high impact polystyrene, and Techtron® HPV 
Bearing grade plastic [28]. These materials were all measured to be within IROC-H’s 
“proton equivalent” criteria, that is to be within 5% of M.D. Anderson Cancer Center’s 
Eclipse HU vs. RLSP CT calibration curve [6].  
42 
 
2.2 CT scans 
2.2.1 CT Scanner Constancy 
HU values of the materials in the proton CT phantom were measured on the clinical CT 
simulation scanners at MD Anderson’s PTC-H and Ambulatory Clinical Building (ACB). To 
ensure the reliability of HU measurements, multiple measurements were taken at 
varying intervals on the scanners to confirm the constancy of the output. The CT 
phantom was scanned (see Figure 7) and HU was measured for five consecutive days 
and then on a weekly basis for five weeks. The CT scans were performed on the two CT 
machines with parameters shown in Table 1: 
 
Table 1. Parameters of CT Constancy Scans 
Parameter GE Lightspeed 
(Located in PTC-H) 
GE Lightspeed 
(Located in ACB) 
kV 120 120 
Pitch 1.375:1 1.5:1 
Extent S50mm-I50mm S50mm-I50mm 
Beam 
Configuration 
16x0.625 4x1.25 
No. of Images 41 41 
Beam collimation 10 mm 5 mm 
Speed 13.75 mm/rot 7.5 mm/rot 
Matrix size 512 512 
Reconstruction Standard Standard 
DFOV 50 cm 50 cm 
SFOV Large Large 
Rotation speed 0.8 sec 1.0 sec 
 
The setup for the scans is pictured in Figure 9.  
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Figure 9. Setup of CT phantom in CT simulator 
 
The resulting scans were loaded into the iSite (Philips, Amsterdam, The Netherlands) 
interface created by Philips where it was possible to create ROI’s and measure the 
average HU as shown in Figure 10.  Because all measurements were taken with this 
software, consistency between GE equipment and Philips viewing software is not of 
concern. 
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Figure 10. Measurement of HU 
 
 
2.2.2 HU measurement 
Institutions participating in proton audits by IROC-H at this time are using both 120 and 
140 kV, with a majority using 120 kV when imaging the proton lung phantom during 
the CT simulation step of the audit process. These energies were therefore both 
included in this study, with 80 kV being included because of the possible future use of 
dual energy. Dual energy CT (DECT) is gaining momentum as a modality for simulations 
[29] and most methods of DECT use 80 kV as the lower energy used for increased 
contrast [30]. In the event that institutions participating in IROC-H QA begin using DECT 
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for simulations, it is valuable to understand how this change could affect the random 
uncertainty in the IROC-H QA process. It is also valuable to include this large range of 
CT techniques used to evaluate worst case scenarios for criteria used by institutions, in 
the event that an institution may be trying to simulate a special procedure involving 
uncommon criteria.  
CT scans were taken of the proton CT phantom using 3 different CT techniques, 80 kV, 
120 kV, and 140 kV to investigate changes in the proton CT calibration curve as a 
function of CT technique. For each CT beam quality, ten scans were taken of the proton 
CT phantom and the HU of each phantom material was averaged for a given energy to 
input into a unique proton CT calibration curve.  
2.3 Determination of Proton RLSP 
2.3.1 Tissue substitution method 
The RLSP of each material in the proton CT phantom was determined using the tissue 
substitution method described by Moyers using a passive scatter proton beam on 
gantries 1 and 2 at the PTC-H. This method was introduced in the previous chapter.  
To determine the RLSP for a material using this method, a slab of the material is placed 
in front of a water phantom and central axis depth dose curve measurements with the 
beam passing through the material are taken with an ionization chamber. A second 
depth dose curve in water only is measured without the material in the proton beam. 
RLSP is then calculated according to Equation 6 as previously defined.  
 
An electronic caliper was used to measure the average thickness of each measureable 
material in the CT phantom as detailed below in Table 2. 
 
Table 2. Thickness of CT phantom materials 
Material Average Thickness [cm] 
Polyethylene 7.0167 ± 0.0099 
Balsa wood 7.0037 ± 0.0018 
Blue water 7.0087 ± 0.0008 
HPV 6.9690 ± 0.0080 
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Presage® 6.9200 ± 0.0066 
 
Instead of using a water phantom and ionization chamber as Moyers suggested, this 
project used a Zebra multi-layer ion chamber (MLIC) (IBA, Bartlett, USA) designed to 
simulate a water phantom to determine proton depth dose curves. The Zebra is an 
MLIC produced by IBA for high precision particle therapy dosimetry and is shown in 
Figure 11.  
 
 
Figure 11. Zebra MLIC 
 
It is comprised of 180 plane parallel ionization chambers spaced 2 mm apart with a 
removable 1 mm WET buildup block to increase the resolution of measurements [31]. 
The buildup screen was not used in this experiment because there was not a need for 
the increased precision of measurements. Each proton CT phantom material was 
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placed in the beam path near the front window of the Zebra to acquire the data to 
create the proton depth dose curves with the material in place. 
 
The Zebra utilizes the OmniPro-Incline software, also produced by IBA, for the 
measurement and analysis of depth dose curves. The software allows the user to 
manually select the plateau region as well as manually defining the background 
locations on the depth dose profile in order to calculate the R90 that can be used in the 
RLSP calculation. These defined areas can be seen below in Figures 12 and 13 and the 
resulting compilation of depth dose profiles measured by the Zebra and reported by 
Incline can be seen in Figure 14.  
 
 
 
Figure 12. Selection of plateau in Incline 
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Figure 13. Selection of background in Incline 
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Figure 14. Depth Dose Profiles Measured by Zebra and Analyzed by Incline 
 
At low proton energies, such as the 140 MeV beam used for this project, the SOBP is 
very shallow and can be only partially measured by the Zebra when the proton 
equivalent materials are placed in front of the Zebra. Because of this specific issue, the 
R90,material had to be manually determined from the incomplete measured SOBPs for 
blue water, Presage®, bone equivalent, and polyethylene to calculate the 140 MeV 
RLSP measurements.  
 
Three sets of RLSPs were calculated using Equation 6 as previously defined for each 
material with each set corresponding to a specific proton energies, 140, 200, and 250 
MeV.  
 
2.4 Creation of custom calibration curves 
Nine separate custom HU to RLSP proton CT calibration curves were created using three 
different CT techniques and 3 different proton energies. 7 different materials were 
measured for HU and corresponding RLSP under each of the 9 different sets of conditions. 
An example of a curve plotting HU against RLSP is shown below in Figure 15 for a single CT 
technique and proton energy pair, with each point representing a material from the proton 
CT phantom. All nine of the custom curves created can be found compiled in Chapter 3 and 
individually in Chapter 5.  
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Figure 15. CT Calibration Curve for 120 kV CT technique and 140 MeV proton energy 
 
Each generated proton CT calibration curve was imported into the Eclipse treatment 
planning system (Varian, Palo Alto, CA) to be used during treatment planning. The curves 
were imported manually, one point at a time. To be used by the treatment planning system, 
the curves were modified by extending to the minimum and maximum HU values in order 
to be read by the planning system software. It was assumed that all values above 1500 
would have the same RLSP and so the curve was extended to the maximum HU, 3071, at 
the same RLSP to ensure the inclusion of every pixel above 1500 HU in the treatment plan. 
This same method was also employed at the low end of the HU spectrum. The curve was 
extended to the lowest possible HU value, -1024, and defined with the same RLSP as air in 
order to ensure the inclusion of all pixels with HU values below that measured for air.  
 
In addition to the extension of each curve to meet Eclipse requirements, the curves were 
also altered to have only increasing values to meet Eclipse requirements. The curves specific 
to the 250 MeV proton energy already had this feature, but the curves specific to 140 and 
200 MeV were altered to fit this requirement due to the RLSP of polyethylene being higher 
than its adjacent material, water. This was accomplished through an HU override feature 
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available in the Eclipse treatment planning system. This method involved defining 4 new 
contours for each plan that used a curve specific to 140 or 200 MeV. The region to be 
redefined was the area under the curve starting from the HU at which the curve first has an 
RLSP equal to unity up to the HU at which the curve has an RLSP equal to unity for a second 
time (the point defined by water). This region was divided into 4 sub-regions based on the 
maximum RLSP and half of the maximum RLSP. A thresholding tool was used to define four 
contours (labeled Override1 through Override4) that encompassed all of the pixels with HU 
defined in these sub-regions.  
 
The average RLSP of each of the four regions was determined and the corresponding HU for 
the region of the curve in which HU > 0 was used to override the originally assigned HU 
value. In this manner the RLSP on the calibration curve in the entire region being redefined 
could be set as unity to satisfy the requirement of Eclipse because all HU values in this 
region have been redefined as described for the purposes of dose calculations. An example 
of these Override contours for the plan utilizing the 120 kV, 140 MeV calibration curve is 
shown below in Figures 16-18. 
 
In reality, Eclipse will not allow any points on the CT calibration curve to have the same RLSP 
or HU, so 0.001 was added or subtracted from RLSP values as necessary to fulfill this 
requirement. This was determined to not be a significant source of uncertainty in the results 
of this project.  
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Figure 16. Contours for CT Overrides at Isocenter in Axial View 
 
 
Figure 17. Contours for CT Overrides at Isocenter in Coronal View 
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Figure 18. Contours for CT Overrides at Isocenter in Sagittal View 
 
 
All 9 curves were loaded separately into the Eclipse treatment planning system under beam 
administration to be available for application to any treatment plan in the Research Eclipse 
system.  
 
2.5 Treatment planning 
The Research Eclipse treatment planning system at PTC-H was used for all treatment 
planning in this project. Nine treatment plans were created for the proton lung phantom, 
with one plan for each of 9 calibration curves created using varying combinations of CT 
technique and proton energy as described previously. The three data sets taken of the 
proton lung phantom with the CT simulator were used for treatment planning. Data sets 
were taken at three CT techniques: 80, 120, and 140 kV.  
 
54 
 
In this study, treatment plans using a calibration curve created with a specific CT technique 
were planned on the data set created at that same CT technique (for example, all plans that 
use a calibration curve created with a 120 kV CT technique will be planned on the 120 kV 
data set acquired as described in previous sections).  
 
All plans were created using a proton energy of 140 MeV because it a typical energy used by 
institutions performing these lung phantom audits. Planning at the 200 and 250 MeV proton 
energies was not pursued in this project due to practical issues of the phantom size and 
design. Higher energies would not allow the SOBP to easily be placed at the target in the 
phantom without additional manipulation.  
 
All plans were created with the following contours: Body, Lung, Heart, PTV, Target, and TLD. 
4 additional CT override contours were created for each plan using a CT calibration curve 
made using 140 or 200 MeV protons. An example of all of these contours can be seen below 
in Figure 19 in the plan created for use with the 120 kV / 140 MeV CT calibration curve.  
 
 
Figure 19. Contours used in treatment planning 
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Institutions participating in previous proton audits have created treatment plans with a 
variety of beam arrangements. The beam arrangement chosen for this project is a common 
orientation used by institutions and is the most easily reproducible for irradiations of the 
phantom. This study chose to create all plans with two fields, an AP beam at 0° and a left 
lateral beam at 90°. A compensator and block was created for each beam. Table 3 outlines 
parameters in every plan used for the purposes of treatment planning. All plans have 
identical parameters with the exception of CT dataset and CT calibration curve. 
 
Table 3. Treatment planning parameters 
Proton energy 140 MeV 
Distal margin 0.6 cm 
Proximal margin 0.3 cm 
Reference point Target 
Nominal SAD 270 cm 
Technique Double Scattering 
Machine G2 
Isocenter (-0.34 cm, -3.10 cm, 1.85 cm) 
Snout size Medium 
SOBP width 4.0 cm 
Field 1 Nominal range 9.88 cm 
Field 2 Nominal range 8.76 cm 
Plan normalization value 97.00 
Total dose 600 cGy 
Fractions  1 
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2.6 Dose comparison 
2.6.1 Dose Volume Histogram (DVH) Comparison 
DVH’s compare the percent volume of a specified structure that receives a given dose. 
These are useful in maintaining safe and effective radiation treatments for patients 
because they allow the monitoring of specific organs and regions. Target regions can be 
monitored to ensure they receive an acceptably high dose and organ doses can be 
monitored to ensure they remain acceptably low to avoid any adverse effects to the 
patient.  
The DVH relationship is used in this study to ensure the created treatment plans are 
clinically viable and meet any clinical constraints. It also provides an additional way to 
compare the 9 treatment plans created for this study.  
2.6.2 Gamma Analysis 
2.6.2.1 3D Gamma Index Analysis 
The primary goal of this study was to compare the dose distributions of treatment 
plans created using the different CT calibration curves created under varying 
parameters outlined above. The comparisons were made between the various 
treatment plan volumetric dose distribution data sets assessing agreement using a 3D 
Gamma Index analysis tool with a ±3%/5mm criteria. This is problematic for the original 
CERR program, but updates to the software have incorporated the ability to compare 
two 3D dose files.  
 
From the Eclipse treatment planning system it is possible to export a DICOM RT dose 
file. Because CERR can only read one dose file at a time, it must be exported as a single 
total dose and not individual dose files from each field. CERR has the capability of 
converting these files, which are exported as DICOM files, into matlab files.  
 
This study compared multiple plans to a single reference plan. This reference plan was 
defined as the plan created with a CT calibration curve corresponding to the CT scan 
using 120 kV and a proton energy of 140 MeV. This plan was chosen as reference 
because these parameters are the most appropriate clinically and most widely used for 
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the proton lung phantom due to its size and composition. A total of 8 comparisons to 
the reference plan were made using CERR’s 3D gamma index analysis tool.  
 
To perform a 3D gamma analysis in CERR the reference dose file must be converted 
from a DICOM RT file to a matlab file and can then be imported into the CERR viewer. 
Then each successive DICOM RT dataset for each treatment plan is imported and CERR 
gives the user the option to choose individual plans for 3D gamma comparison. The 3D 
gamma function provides the user with gamma statistics as well as a visual 
representation of the gamma results which can be found in the Appendix of this report. 
2.6.2.2 2D Gamma Index Analysis  
In addition to a 3D gamma analysis, a 2D gamma analysis was also performed between 
the reference plan axial, coronal and sagittal slices going through the isocenter and the 
corresponding slices for each of the other eight plans. The same gamma analysis 
criteria of 3%/5mm was used for these comparisons. This 2D evaluation was performed 
because the IROC-H anthropomorphic proton phantoms use radiochromic films in the 
sagittal, coronal and axial planes to measure the dose distribution delivered to the 
phantoms and to compare to the dose distribution calculated by the institution’s 
treatment plan. Because the film is planar, the only comparisons that can be done are 
2D gamma analyses. Therefore it was necessary to mimic how the proton phantoms are 
actually used and analyzed to determine whether the variations in CT technique and 
proton beam energy tested would have any impact on the phantom/institution 
comparison results.  This 2D analysis was also of interest to show differences between 
the 3D gamma analysis versus the 2D gamma analysis because it has been shown that 
3D gamma analyses result in a higher pass rate than 2D gamma analyses [32].  
 
The 2D gamma analysis was performed with the OmniPro I’mRT software created by 
IBA. The region of interest (ROI) was tightened to contain only the target and adjacent 
low dose regions to avoid the skewing of the results from including a high number of 
pixels with very low dose.  This was performed for a plane at isocenter in all three 
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spatial planes, axial, coronal and sagittal. An example of the ROI chosen can be seen 
below in Figures 20-22.  
 
 
 
Figure 20. 2D gamma analysis of axial slice at isocenter comparing the study reference plan to 
the plan corresponding to 140 kV and 250 MeV. 
 
  
Figure 21. 2D gamma analysis of coronal slice at isocenter comparing the study reference plan 
to the plan corresponding to 140 kV and 250 MeV 
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Figure 22. 2D gamma analysis of sagittal slice at isocenter comparing the study reference plan 
to the plan corresponding to 140 kV and 250 MeV 
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Chapter 3 
 
3 Results and Discussion 
3.1 Aim 1 (HU/RLSP determination and calibration curve creation) 
 The goal of the first specific aim was to measure the HU and RLSP of designated materials 
and then create custom calibration curves to be used in treatment planning. The first step in 
creating custom curves was to measure the HU of each material in the proton CT phantom 
for each of three CT techniques: 80, 120, and 140 kV. The first step in this process was to 
measure the constancy of the CT scanner over time and the results of this can be seen 
below. Measurements were taken daily for five days and then weekly for a subsequent 5 
weeks. The results are pictured below in Figure 23 with the standard deviation of each 
material visualized in Figure 24.  
 
 
Figure 23. Constancy of HU values on MD Anderson CT simulation scanners 
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Figure 24. HU variability of CT phantom materials 
 
These figures show that the largest deviations occur in bone. This is expected due to the 
high density of the material and potential for beam hardening or streaking artifacts. A 
similarly high deviation is seen for air. This stability over time is comparable to that seen in 
QA at PTC-H as well as in literature [33]. 
 
The resulting HU values measured at multiple CT energies can be seen below in Table 4. 
Only minor differences in the HU of the low density materials (air and balsa wood) were 
observed, but for the other materials, excluding water, the points of normalization, 
differences in HU were observed between the 3 CT energies. The largest difference, up to 
an approximately 80% difference, was observed between the 80 kV and the two other CT 
techniques. The maximum percent change between 120 and 140 kV was observed for 
polyethylene with a 17% change. Moyers reports a small change in RLSP due to non-
standard CT techniques at low atomic numbers that increases with increasing atomic 
number [7]. We see this same increasing deviation as the density of material increases [34].  
 
Table 4. Measured HU at three CT techniques 
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HU 
Material 80 kV 120 kV 140 kV 
Air -981.90 -982.79 -980.58 
Balsa wood -695.56 -693.48 -693.28 
Polyethylene -85.29 -55.53 -47.62 
Water 3.55 2.00 2.69 
Blue water 159.01 120.48 111.67 
Presage® 191.09 152.72 143.53 
Bone 757.61 571.17 528.69 
 
In addition to HU, the RLSP was measured for each material in the CT phantom at each of 
three proton energies: 140, 200, and 250 MeV. These results can be seen in Table 5 below. 
The resulting variation in RLSP as a function of proton energy was very small. The maximum 
difference was observed for the balsa wood material showing a 7.3% increase in the RLSP 
going from 250 MeV to 140 MeV. As the density of the materials increased, the variation in 
RLSP decreased to be less than 1%.  
 
The HU for air listed in Table 4 were measured in the air hole of the proton CT phantom. 
Literature has reported up to a 1.8% difference in HU of air measuring inside and outside a 
phantom and this could therefore be an additional source of uncertainty in the HU 
measurements [35].  
 
These data in Table 5, except for the lung equivalent material of balsa wood, agree with the 
data published by Moyer et al that reported an energy dependence of <1.2% for soft tissues 
[7].  
 
Balsa wood is used to simulate lung tissue the maximum difference in RLSP due to proton 
energy in this material could be a cause for concern[36]. The data indicate larger differences 
in RLSP that would result in larger changes in proton range, altering the dose distribution. 
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This is relevant for the lung phantom and this material because of the possibility of larger 
errors in the structure of interest during lung irradiations of this IROC-H phantom.  
 
Table 5. Measured RLSP at three proton energies for the 120 kV CT technique 
 
RLSP 
Material 140 MeV 200 MeV 250 MeV 
Air 0.000 0.000 0.000 
Balsa wood 0.355 0.345 0.331 
Polyethylene 1.014 1.016 0.996 
Water 1.000 1.000 1.000 
Blue water 1.068 1.067 1.067 
Presage® 1.082 1.085 1.085 
Bone 1.290 1.281 1.277 
 
Proton CT calibration curves were created by plotting HU versus RLSP for all combinations 
of CT technique and proton energy. These custom curves were compared to the calibration 
curve currently used clinically by the Eclipse proton treatment planning system at UT MD 
Anderson Cancer. This comparison is relevant because the currently used curve was created 
with the same equipment used to create the custom calibration curves for this project. 
Figure 25 below pictures the clinically used calibration curve as a reference compared to all 
9 of the custom curves created for this experiment. The large dashed line depicts a 3% 
difference from the clinical reference curve and the smaller dashed line depicts a 5% 
difference from the clinical reference curve. 
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Figure 25. Custom CT calibration curves with clinical reference curve 
 
As seen in Figure 25 above, the polyethylene material is the material with the largest 
difference from the clinical reference. For each curve seen above polyethylene is the 
material with HU ranging from -48 to -83. This data shows RLSP values for polyethylene 
greater than unity, causing the CT calibration curves to not have constantly increasing 
RLSPs. While this can be an issue for practical reasons with the treatment planning system, 
this is consistent with data found in the literature and therefore not a cause for concern [7]. 
This figure can be reexamined without the effects of polyethylene in Figure 26 below. 
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Figure 26. Custom CT Calibration curves with clinical reference curve excluding polyethylene 
 
With the exclusion of polyethylene, most points on the curve fall within the ±5% boundary. 
It can be seen that at low CT techniques (80 kV) the curve begins to fall further away from 
the reference at higher HU values. For a given material of any HU, the maximum difference 
in predicted RLSP between the clinical reference curve and the custom curve is 12%. Due to 
the Bragg peak associated with steep proton dose gradients, errors in proton dose delivery 
could be significant if the edge of the peak lies close to an interface with a high density 
material, as this data shows RLSP has a maximum deviation in high density materials such as 
bone. This high deviation at low CT could pose a problem for institutions if they were 
imaging patients under this very low CT technique and the patient had metal implants, for 
example. In this scenario it would be recommended to the clinic to override high density 
materials for treatment planning.  
 
The custom calibration curve can also be visually compared to the “reference” curve 
defined by this project as the curve created with 120 kV CT technique and 140 MeV proton 
energy. This difference can be seen below in Figure 27. The 3% and 5% differences are 
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defined from the reference curve for this study rather than the clinical reference curve 
here.  
 
 
Figure 27. Custom CT Calibration curves with 120 kV/ 140 MeV reference curve including 
polyethylene 
 
When polyethylene is included, the curves stay within 3% difference of the 120 kV/140 MeV 
reference curve pictured in Figure 27 to a much higher degree than the 3% difference line of 
the clinical reference curve shown in Figure 25. The same drift of RLSP corresponding to low 
kV (80 kV) away from the reference can be seen. For a given material of any HU, the 
maximum difference in predicted RLSP between the study reference curve and the custom 
curve is 7%, lower than that between the clinical reference curve and the custom curve.  
 
An example of the modified calibration curves to be input into the Eclipse treatment 
planning system is shown below in Figure 28. It is shown compared to the reference curve 
currently used in the clinic at PTC-H.  
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Figure 28. CT Calibration Curve for Input into Eclipse Treatment Planning System Corresponding 
to 120 kV CT Technique and 140 MeV Proton Energy 
 
Additionally, the uncertainty in material thickness was examined to determine the possible 
effect on RLSP that would translate to deposited dose. These results can be seen below in 
Table 6. 
Table 6. Effect of material thickness on RLSP 
 
140 MeV 200 MeV 250 MeV 
Material 
RLSP Difference 
[MeV cm2/g] 
RLSP Percent 
Difference 
RLSP Difference 
[MeV cm2/g] 
RLSP Percent 
Difference 
RLSP Difference 
[MeV cm2/g] 
RLSP 
Percent 
Difference 
Polyethylene 0.001 0.140 0.001 0.140 0.001 0.140 
Balsa wood 9.27E-05 0.026 9.00E-05 0.026 8.63E-05 0.026 
Blue water 0.000 0.012 0.000 0.012 0.000 0.012 
HPV 0.001 0.115 0.001 0.115 0.001 0.115 
Presage® 0.001 0.095 0.001 0.095 0.001 0.095 
  
Table 6 shows that the uncertainty in the material thickness leads to a maximum change in 
RLSP of 0.001 across all materials and proton energies. 0.001 is the smallest unit of RLSP 
difference that the Eclipse treatment planning system can differentiate and therefore would 
not lead to a meaningful change in dose distribution.  
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3.2 Aim 2 (Creation of plans) 
The goal of aim 2 was to incorporate the custom CT calibration curves into the Eclipse 
treatment planning system to create 9 different treatment plans to evaluate their effects on 
the resulting dose distributions to see if there were any measurable differences. The 9 
different dose distributions were calculated by the planning system based on the given RLSP 
provided by the custom curve and the subsequent calculated proton range and deposited 
dose.  
 
3.2.1 Dose Volume Histograms (DVH) 
The DVHs for three organs (heart, lung, and target) for each plan was examined in 
the treatment planning system and compared to clinical standards to assess the 
quality of the treatment plan. The DVHs between the 9 plans were also compared 
as a measure of differences due to the varying CT technique and different proton 
energy. An example DVH of the plan corresponding to 120 kV CT technique and 
140 MeV proton energy can be seen below in Figure 29. The remaining 8 DVH’s for 
all plans can be found in the Appendix. In Figure 29, the dose to the heart is shown 
in yellow, the dose to the lung is shown in blue, and the dose to the target is 
shown in cyan. This color scheme is followed for all DVH’s shown for this study.  
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Figure 29. Heart, lung, and target DVH of plan corresponding to 120 kV CT technique and 140 
MeV proton energy 
 
Based on the DVH in Figure 29 above, the 3 organ structures met the clinical 
constraints and goals. The heart dose is very low, and remains so for all plans, and 
is below clinical critical limits [37]. The target dose achieved its goal of >100% of 
the prescription dose of 600 cGy and this too is consistent throughout all 9 plans. 
However, the lung dose, as measured with the V20% (percent of the lung volume 
receiving 20% of the prescription dose), varied slightly between plans as shown 
below in Table 7.  
 
Table 7. DVH of lung for various treatment plans 
Plan [kV_MeV] V20% [%] 
80_140 24 
80_200 25 
80_250 26 
120_140 24 
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120_200 24 
120_250 24 
140_140 24 
140_200 25 
140_250 26 
 
V20% is a metric describing the dose is a standard used clinically to predict lung 
complications and is kept below 30-35% at MD Anderson Cancer Center for 
treatment with radiation therapy alone [37][38]. All V20% values for plans in this 
study are below this 40% threshold and these plans are therefore considered 
acceptable. The variation noted in V20% between the different plans ranged from 
24% to 26% with the reference lung treatment parameters of 120 kV/140 MeV 
having a V20% of 24%. These data suggest that regardless of the proton beam 
energy or CT technique used, the resulting proton dose distributions would not 
impact the lung dose in any great amount. 
3.2.2 HU Overrides 
 
3.3 Aim 3 (Analysis of plan differences) 
3.3.1 3D gamma analysis 
A 3D gamma analysis, using the CERR software, was performed as described in 
previous sections between the reference lung treatment plan corresponding to 120 
kV CT technique and 140 MeV proton energy.  
 
Recall that this study is examining the hypothesis that the variations in the 
treatment plans caused by the different CT techniques and proton beam energy 
RLSP values will reduce the percent of passing pixels by 10% using a gamma criteria 
of ±3%/5mm. A threshold of 5% was used for both 3D and 2D gamma analyses. 
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Shown below in Figure 30 are the results of the percent of pixels passing the 3D 
gamma index criteria of ±3%/5mm for each of four contoured structures for each 
of the 8 plans as compared to the 120 kV/140 MeV.  
 
 
Figure 30. 3D gamma analysis of 120 kV/ 140 MeV treatment plan compared to all other 
treatment plans created for this study with a gamma criteria of 3%/5mm 
 
These 3D gamma analysis results are displayed for different contours in the plan. 
The primary contour of interest is the Target contour as this is the section of the 
phantom used for analysis in IROC-H audits using the proton lung phantom. As 
shown above, every plan has a Target with a 100% rate of passing pixels. The 
variation in CT technique and proton beam energy had no effect on the Target 
dose. The lowest passing rate of pixels is found in the lung, likely due to the large 
volume and heterogeneous nature of the lung material. However, this pass rate is 
still very high, 98.4%, far below our hypothesized 10% reduction. Although not of 
primary interest, the gamma evaluation of the Body and Heart contours are also 
included in Figure 30 for reference with the goal of pinpointing any failing pixels. 
An example of the spatial representation of this gamma analysis with a ±3%/5mm 
criteria can be seen in Figure 31 below. While not included in the ROI of the 
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gamma analysis, there were areas at the distal end of each proton beam that 
showed some disagreement. This was to be expected due to the observed 
differences in the RLSPs as a function of beam energy for the low density tissue 
substitutes. While there appear to be some localized differences, the impact on the 
overall lung dose is minimal and has no impact on the Target dose. A full set of 
visual representations of these gamma analyses at isocenter can be seen in the 
Appendix.  
 
 
Figure 31. Gamma analysis at isocenter of plan corresponding to study lung reference curve 
compared with plan corresponding to 80 kV and 250 MeV with gamma criteria 3%/5mm 
 
Because the percent of passing pixels was so high for the hypothesis criteria, there 
was interest in the effects of variable gamma criteria. Shown below in Figure 32 are 
the results of a gamma analysis performed on the same plans as described 
previously, but with an extremely tight gamma criteria of ±1%/1mm.   
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Figure 32. 3D gamma analysis of 120 kV/ 140 MeV treatment plan compared to all other 
treatment plans created for this study with a gamma criteria of 1%/1mm 
 
From these gamma tests, it can be seen that although the majority of the Targets 
maintains a 100% pixel passing rate (one Target had a percent of passing pixels of 
99.5%), the lung becomes a good representation of the change experienced due to 
the varying treatment plans. From this it can be seen that the lowest passing rate is 
associated with the 250 MeV proton energy, for both 80 kV and 140 kV, yet no 
plans resulted in greater than a 5.6% change, still less than the hypothesized 10% 
change. This lack of dependence on CT technique is in contrast to the CT calibration 
curves alone, which showed a large difference at a low CT technique. The lower 
pass rate also seen here at the highest proton energy, 250 MeV, for all CT 
techniques, is not reflected in the CT calibration curve differences noted earlier. It 
is possible that the percent of pixels passing at 1%/1mm criteria is not an 
appropriate metric when comparing the variations in the CT calibration curves and 
the resulting treatment planning system calculated dose distributions. There are 
approximations in the planning system dose calculations that possibly cannot 
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distinguish differences at the 1%/1mm level. These approximations would be 
especially problematic for such tight criteria if registering of images was involved. 
 
An example of the spatial representation of this gamma analysis with 1%/1mm 
criteria at the isocenter can be seen in Figure 33 below. A full set of visual 
representations of these gamma analyses at isocenter can be seen in the Appendix. 
 
 
Figure 33. Gamma analysis at isocenter of plan corresponding to study reference curve 
compared with plan corresponding to 80 kV and 250 MeV with gamma criteria 1%/1mm 
 
The gamma criteria were then further tightened with the goal of approaching the 
point of failing, defined as <90% of passing pixels. This test was only performed for 
the study reference curve compared to the curve corresponding to 80 kV and 250 
MeV due to its already established lower passing rate. With the criteria tightened 
to 0.5%/0.5mm, the results of a gamma test for all contours in this comparison are 
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shown below in Figure 34. Even with this unrealistic gamma criteria, the difference 
in pixels did not ever exceed 10%. Varying the CT technique and proton beam 
energy did not negatively impact any of the comparisons for any of the 9 plans.  
 
 
Figure 34. Results of 3D gamma analysis of plan using study reference curve compared to the 
curve corresponding to 80 kV CT technique and 250 MeV proton energy 
 
An example of the spatial representation of this gamma analysis with 0.5%/0.5mm 
criteria at the isocenter can be seen in Figure 35 below.  
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Figure 35. Gamma analysis at isocenter of plan corresponding to study reference curve 
compared with plan corresponding to 80 kV and 250 MeV with gamma criteria 0.5%/0.5mm 
 
3.3.2 2D gamma analysis 
Due to the very high pass rates of the 3D gamma analysis the difference between 
3D analyses and 2D analyses was investigated.  
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Figure 36. 2D gamma analysis of 120 kV/ 140 MeV treatment plan compared to all other 
treatment plans created for this study with a gamma criteria of 3%/5mm 
 
Recall that this gamma analysis was done for all three planes, axial, coronal and 
sagittal, comparing the study lung reference plan (120 kV/140 MeV) to all other 
plans created for the study. As shown in Figure 36, it is possible to see that the 
lowest number of passing pixels using a gamma index criteria of ±3%/5mm occurs 
for the comparison between the study reference plan and the plan corresponding 
to 140 kV and 250 MeV, contradicting the maximum difference seen in the CT 
calibration curves at a low 80 kV technique, but consistent with the results of the 
3D gamma analysis. At the hypothesis gamma criteria of 3%/5mm, a spatial 
representation of this gamma analysis can be seen below in Figures 37-39 for the 
three spatial planes. The only differences noted are at the distal ends of each 
treatment beam because of the measured differences in lung RLSPs. The remaining 
2D gamma representations and profiles can be seen in the Appendix.  
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Figure 37. 2D gamma analysis of axial slice at isocenter comparing the study reference plan to 
the plan corresponding to 140 kV and 250 MeV with gamma criteria of 3%/5mm 
 
 
 
Figure 38. 2D gamma analysis of coronal slice at isocenter comparing the study reference plan 
to the plan corresponding to 140 kV and 250 MeV with gamma criteria of 3%/5mm 
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Figure 39. 2D gamma analysis of sagittal slice at isocenter comparing the study reference plan 
to the plan corresponding to 140 kV and 250 MeV with gamma criteria of 3%/5mm 
 
The 2D gamma analysis was repeated with a tighter gamma criteria, as was performed 
with the 3D analysis. The plan with the maximum difference, as determined by the 
percent of passing pixels using a ±3%/5mm gamma index analysis, is seen in Figure 36 
to be the plan corresponding to 140 kV and 250 MeV. A threshold of 5% was used. The 
gamma analysis was also run with the tightened criteria of 1%/1mm with the same 
threshold for the same two plans and the results are seen below in Figures 40-42. The 
actual % of pixels passing the 1%/1mm criteria are listed in Table 8. 
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Figure 40. 2D gamma analysis of axial slice at isocenter comparing study reference plan to the 
plan corresponding to 140 kV and 250 MeV with gamma criteria of 1%/1mm 
 
 
 
Figure 41. 2D gamma analysis of coronal slice at isocenter comparing study reference plan to 
the plan corresponding to 140 kV and 250 MeV with gamma criteria of 1%/1mm 
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Figure 42. 2D gamma analysis of sagittal slice at isocenter comparing study reference plan to 
the plan corresponding to 140 kV and 250 MeV with gamma criteria of 1%/1mm 
 
This tightened criteria of 1%/1mm is quantified in Table 8 below.  
 
Table 8. 2D Gamma results for study reference plan compared to 140 kV and 250 MeV plan with 
gamma criteria of 1%/1mm 
 
% Passing 
Pixels 
Axial 96.22 
Coronal 97.91 
Sagittal 97.58 
 
A gamma criteria of 1%/1mm is much tighter than that used clinically or by IROC-H. 
Even at this very tight criteria, the passing pixel percentage was well above the 
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hypothesized 90% needed for the plan to pass, indicating a low level of influence due to 
variable CT technique and proton energy in the creation of CT calibration curves even 
using a 2D gamma analysis.  
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Chapter 4 
4 Conclusions 
4.1 Meeting of specific aims 
 
The goal of this project was to understand the uncertainty in the proton CT calibration 
curves at proton institutions and its influence on the credentialing and auditing process 
(E2E anthropomorphic QA phantom irradiation) performed by IROC-H that might stem 
from variable CT technique and proton energy. This project further looked at how this 
uncertainty might translate to uncertainties in dose distributions. The hypothesis of this 
project was to determine if this variable CT technique and proton energy would lead to 
a change in dose distribution resulting in more than 10% of failing pixels with a gamma 
analysis criteria of ±3%/5mm.  
 
The first specific aim was to measure the HU and RLSP of phantom materials and create 
custom calibration curves. This was accomplished with the proton CT phantom 
containing 6 proton equivalent materials currently used by IROC-H on proton institution 
site visits. All of the custom curves were compared to the clinical reference curve used 
at MD Anderson’s PTC-H and the reference curve (120 kV and 140 MeV) used for this 
study. It was found that the maximum difference in predicted RLSP between the clinical 
reference curve and the custom curves was no more than 12%. The maximum 
difference in predicted RLSP between the study’s reference curve and the custom 
curves was 7%. This completed specific aim one and laid the ground work for aims two 
and three as well as provided as initial reference when comparing dose differences.  
 
The second specific aim involved the creation of 9 treatment plans for IROC-H’s proton 
lung phantom and was accomplished simultaneously with the first part of specific aim 
three which required uploading the custom calibration curves into the Eclipse 
treatment planning system and calculating the plans, each using a different proton CT 
calibration curve. This was accomplished through the beam administration functions of 
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Eclipse as described in previous chapters. Once the custom curves were uploaded and 
assigned to treatment plans it was possible to calculate the plans and get dose 
distributions specific to each set of parameters.  
 
Specific aim 3 was the evaluation and analysis of the treatment plans created in specific 
aim two. Both 3D and 2D gamma analyses were performed to evaluate the hypothesis 
as described in previous chapters. The hypothesis stated that the passing rate must be 
reduced by more than 10% passing pixels at a gamma criteria of 3%/5mm, meaning a 
pass rate of less than 90% for any treatment plan compared to the study’s reference 
plan. At this gamma criteria, the percent of passing pixels for the Target structure was 
100%. Zero percent of pixels failing implies that the changing plans from the various CT 
techniques and/or proton beam energy have no substantial effect on the dose 
distribution. Following from this, we can conclude that the use of proton CT calibration 
curves with variable CT technique and proton energy is not a substantial source of 
uncertainty in IROC-H’s end to end (E2E) credentialing and auditing QA processes that 
use the proton anatomic phantoms and is not contributing to any institution failing a 
proton audit.  
 
This refutes the hypothesis defined for this study that states: 
 
Variations in CT technique and proton energy will alter the delivered dose distributions 
of typical proton treatments by reducing the percent of passing pixels by 10% using a 
gamma analysis criteria of ±3%/5 mm as measured using a heterogeneous proton QA 
phantom.  
 
4.2 Clinical significance 
IROC-H provides QA services to institutions participating in NCI funded clinical trials 
involving proton therapy. The purpose of IROC-H is to ensure that institutions are 
delivering accurate and comparable doses, which is accomplished in part by phantom 
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dosimetry audits. In this process it is critical for IROC-H to understand the potential 
uncertainties in the QA phantoms and in the E2E process in order to provide accurate 
feedback. This study adds to the understanding of the uncertainty in this process with 
the goal of improving institution feedback and therefore improving clinical trial data 
and cancer care.  
4.3 Future work 
The results of this project resulted in conclusions that rejected the stated hypothesis 
and therefore open the door for additional studies to address the problem described in 
Chapter 1. The increased failure rate of institutions participating in proton QA through 
IROC-H continues to have an unknown source and steps should be taken in the future 
to investigate this uncertainty further.  
 
It could be valuable to determine how this uncertainty is seen in a scanning beam, 
although expected differences would be low because the measurement of RLSP would 
remain consistent. Additionally the addition of motion, frequently used in IROC-H 
proton audits with the lung phantom, could also add a level of uncertainty not 
evaluated in this project.  
 
The continued presence of an uncertainty in the auditing process of IROC-H can lead to 
additional institution failures and reduces the reliability of the QA services provided by 
IROC-H and may negatively affect the availability and quality of data provided to NCI 
funded clinical trials.  
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Chapter 5 
 
5 Appendix 
5.1 Incline 
 
Figure 43. Depth Dose Measured by Zebra at 140 MeV for Various Materials 
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Figure 44. Depth Dose Measured by Zebra at 200 MeV for Various Materials 
 
Figure 45. Depth Dose Measured by Zebra at 250 MeV for Various Materials 
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5.2 Custom curves 
 
Figure 46. CT Calibration Curve with HU Corresponding to 80 kV and RLSP corresponding to 140 
MeV 
 
 
Figure 47. CT Calibration Curve with HU Corresponding to 80 kV and RLSP corresponding to 200 
MeV 
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Figure 48. CT Calibration Curve with HU Corresponding to 80 kV and RLSP corresponding to 250 
MeV 
 
 
Figure 49. CT Calibration Curve with HU Corresponding to 120 kV and RLSP corresponding to 140 
MeV 
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Figure 50. CT Calibration Curve with HU Corresponding to 120 kV and RLSP corresponding to 200 
MeV 
 
 
Figure 51. CT Calibration Curve with HU Corresponding to 120 kV and RLSP corresponding to 250 
MeV 
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Figure 52. CT Calibration Curve with HU Corresponding to 140 kV and RLSP corresponding to 140 
MeV 
 
 
Figure 53. CT Calibration Curve with HU Corresponding to 140 kV and RLSP corresponding to 200 
MeV 
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Figure 54. CT Calibration Curve with HU Corresponding to 140 kV and RLSP corresponding to 250 
MeV 
 
 
Figure 55. CT Calibration Curves with HU Corresponding to 80 kV 
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Figure 56. CT Calibration Curves with HU Corresponding to 120 kV 
 
 
Figure 57. CT Calibration Curves with HU Corresponding to 140 kV 
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Figure 58. CT Calibration Curves with RLSP Corresponding to 140 MeV 
 
 
Figure 59. CT Calibration Curves with RLSP Corresponding to 200 MeV 
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Figure 60. CT Calibration Curves with RLSP Corresponding to 250 MeV 
 
 
5.3 Dose at Isocenter 
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Figure 61. Dose Distribution at Isocenter of Plan Using CT Calibration Curve Corresponding to 80 
kV CT Technique and 140 MeV Proton Energy 
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Figure 62. Dose Distribution at Isocenter of Plan Using CT Calibration Curve Corresponding to 80 
kV CT Technique and 200 MeV Proton Energy 
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Figure 63. Dose Distribution at Isocenter of Plan Using CT Calibration Curve Corresponding to 80 
kV CT Technique and 250 MeV Proton Energy 
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Figure 64. Dose Distribution at Isocenter of Plan Using CT Calibration Curve Corresponding to 
120 kV CT Technique and 140 MeV Proton Energy 
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Figure 65. Dose Distribution at Isocenter of Plan Using CT Calibration Curve Corresponding to 
120 kV CT Technique and 200 MeV Proton Energy 
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Figure 66. Dose Distribution at Isocenter of Plan Using CT Calibration Curve Corresponding to 
120 kV CT Technique and 250 MeV Proton Energy 
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Figure 67. Dose Distribution at Isocenter of Plan Using CT Calibration Curve Corresponding to 
140 kV CT Technique and 140 MeV Proton Energy 
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Figure 68. Dose Distribution at Isocenter of Plan Using CT Calibration Curve Corresponding to 
140 kV CT Technique and 200 MeV Proton Energy 
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Figure 69. Dose Distribution at Isocenter of Plan Using CT Calibration Curve Corresponding to 
140 kV CT Technique and 250 MeV Proton Energy 
 
5.4 CERR Dose Distributions 
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Figure 70. Dose smear provided by CERR for the plan corresponding to 80 kV CT technique and 
140 MeV proton energy 
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Figure 71. Dose smear provided by CERR for the plan corresponding to 80 kV CT technique and 
200 MeV proton energy 
107 
 
 
Figure 72. Dose smear provided by CERR for the plan corresponding to 80 kV CT technique and 
250 MeV proton energy 
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Figure 73. Dose smear provided by CERR for the plan corresponding to 120 kV CT technique and 
140 MeV proton energy 
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Figure 74. Dose smear provided by CERR for the plan corresponding to 120 kV CT technique and 
200 MeV proton energy 
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Figure 75. Dose smear provided by CERR for the plan corresponding to 120 kV CT technique and 
250 MeV proton energy 
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Figure 76. Dose smear provided by CERR for the plan corresponding to 140 kV CT technique and 
140 MeV proton energy 
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Figure 77. Dose smear provided by CERR for the plan corresponding to 140 kV CT technique and 
200 MeV proton energy 
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Figure 78. Dose smear provided by CERR for the plan corresponding to 140 kV CT technique and 
250 MeV proton energy 
 
5.5 CERR 3D Gamma Analysis 
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Figure 79. Gamma analysis at isocenter of plan corresponding to study reference curve 
compared with plan corresponding to 80 kV and 140 MeV with gamma criteria 3%/5mm 
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Figure 80. Gamma analysis at isocenter of plan corresponding to study reference curve 
compared with plan corresponding to 80 kV and 200 MeV with gamma criteria 3%/5mm 
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Figure 81. Gamma analysis at isocenter of plan corresponding to study reference curve 
compared with plan corresponding to 80 kV and 250 MeV with gamma criteria 3%/5mm 
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Figure 82. Gamma analysis at isocenter of plan corresponding to study reference curve 
compared with plan corresponding to 120 kV and 200 MeV with gamma criteria 3%/5mm 
118 
 
 
Figure 83. Gamma analysis at isocenter of plan corresponding to study reference curve 
compared with plan corresponding to 120 kV and 250 MeV with gamma criteria 3%/5mm 
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Figure 84. Gamma analysis at isocenter of plan corresponding to study reference curve 
compared with plan corresponding to 140 kV and 140 MeV with gamma criteria 3%/5mm 
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Figure 85. Gamma analysis at isocenter of plan corresponding to study reference curve 
compared with plan corresponding to 140 kV and 200 MeV with gamma criteria 3%/5mm 
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Figure 86. Gamma analysis at isocenter of plan corresponding to study reference curve 
compared with plan corresponding to 140 kV and 250 MeV with gamma criteria 3%/5mm 
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Figure 87. Gamma analysis at isocenter of plan corresponding to study reference curve 
compared with plan corresponding to 80 kV and 140 MeV with gamma criteria 1%/1mm 
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Figure 88. Gamma analysis at isocenter of plan corresponding to study reference curve 
compared with plan corresponding to 80 kV and 200 MeV with gamma criteria 1%/1mm 
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Figure 89. Gamma analysis at isocenter of plan corresponding to study reference curve 
compared with plan corresponding to 80 kV and 250 MeV with gamma criteria 1%/1mm 
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Figure 90. Gamma analysis at isocenter of plan corresponding to study reference curve 
compared with plan corresponding to 120 kV and 200 MeV with gamma criteria 1%/1mm 
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Figure 91. Gamma analysis at isocenter of plan corresponding to study reference curve 
compared with plan corresponding to 120 kV and 250 MeV with gamma criteria 1%/1mm 
127 
 
 
Figure 92. Gamma analysis at isocenter of plan corresponding to study reference curve 
compared with plan corresponding to 140 kV and 140 MeV with gamma criteria 1%/1mm 
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Figure 93. Gamma analysis at isocenter of plan corresponding to study reference curve 
compared with plan corresponding to 140 kV and 200 MeV with gamma criteria 1%/1mm 
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Figure 94. Gamma analysis at isocenter of plan corresponding to study reference curve 
compared with plan corresponding to 140 kV and 250 MeV with gamma criteria 1%/1mm 
 
5.6 2D Gamma Analysis 
5.6.1 Axial planes 
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Figure 95. 2D gamma analysis of axial slice at isocenter comparing the study reference plan to 
the plan corresponding to 80 kV and 140 MeV with gamma criteria of 3%/5mm 
 
 
Figure 96. 2D gamma analysis of axial slice at isocenter comparing the study reference plan to 
the plan corresponding to 80 kV and 200 MeV with gamma criteria of 3%/5mm 
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Figure 97. 2D gamma analysis of axial slice at isocenter comparing the study reference plan to 
the plan corresponding to 80 kV and 250 MeV with gamma criteria of 3%/5mm 
 
Figure 98. 2D gamma analysis of axial slice at isocenter comparing the study reference plan to 
the plan corresponding to 120 kV and 200 MeV with gamma criteria of 3%/5mm 
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Figure 99. 2D gamma analysis of axial slice at isocenter comparing the study reference plan to 
the plan corresponding to 120 kV and 250 MeV with gamma criteria of 3%/5mm 
 
Figure 100. 2D gamma analysis of axial slice at isocenter comparing the study reference plan to 
the plan corresponding to 140 kV and 140 MeV with gamma criteria of 3%/5mm 
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Figure 101. 2D gamma analysis of axial slice at isocenter comparing the study reference plan to 
the plan corresponding to 140 kV and 200 MeV with gamma criteria of 3%/5mm 
 
Figure 102. 2D gamma analysis of axial slice at isocenter comparing the study reference plan to 
the plan corresponding to 140 kV and 250 MeV with gamma criteria of 3%/5mm 
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5.6.2 Coronal planes 
 
 
Figure 103. 2D gamma analysis of coronal slice at isocenter comparing the study reference plan 
to the plan corresponding to 80 kV and 140 MeV with gamma criteria of 3%/5mm 
Figure 104. 2D gamma analysis of coronal slice at isocenter comparing the study reference plan 
to the plan corresponding to 80 kV and 200 MeV with gamma criteria of 3%/5mm 
135 
 
 
Figure 105. 2D gamma analysis of coronal slice at isocenter comparing the study reference plan 
to the plan corresponding to 80 kV and 250 MeV with gamma criteria of 3%/5mm 
 
Figure 106. 2D gamma analysis of coronal slice at isocenter comparing the study reference plan 
to the plan corresponding to 120 kV and 200 MeV with gamma criteria of 3%/5mm 
136 
 
 
Figure 107. 2D gamma analysis of coronal slice at isocenter comparing the study reference plan 
to the plan corresponding to 120 kV and 250 MeV with gamma criteria of 3%/5mm 
 
Figure 108. 2D gamma analysis of coronal slice at isocenter comparing the study reference plan 
to the plan corresponding to 140 kV and 140 MeV with gamma criteria of 3%/5mm 
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Figure 109. 2D gamma analysis of coronal slice at isocenter comparing the study reference plan 
to the plan corresponding to 140 kV and 200 MeV with gamma criteria of 3%/5mm 
 
Figure 110. 2D gamma analysis of coronal slice at isocenter comparing the study reference plan 
to the plan corresponding to 140 kV and 250 MeV with gamma criteria of 3%/5mm 
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5.6.3 Sagittal planes 
 
 
Figure 111. 2D gamma analysis of sagittal slice at isocenter comparing the study reference plan 
to the plan corresponding to 80 kV and 140 MeV with gamma criteria of 3%/5mm 
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Figure 112. 2D gamma analysis of sagittal slice at isocenter comparing the study reference plan 
to the plan corresponding to 80 kV and 200 MeV with gamma criteria of 3%/5mm 
 
Figure 113. 2D gamma analysis of sagittal slice at isocenter comparing the study reference plan 
to the plan corresponding to 80 kV and 250 MeV with gamma criteria of 3%/5mm 
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Figure 114. 2D gamma analysis of sagittal slice at isocenter comparing the study reference plan 
to the plan corresponding to 120 kV and 200 MeV with gamma criteria of 3%/5mm 
 
Figure 115. 2D gamma analysis of sagittal slice at isocenter comparing the study reference plan 
to the plan corresponding to 120 kV and 250 MeV with gamma criteria of 3%/5mm 
 
141 
 
Figure 116. 2D gamma analysis of sagittal slice at isocenter comparing the study reference plan 
to the plan corresponding to 140 kV and 140 MeV with gamma criteria of 3%/5mm 
 
Figure 117. 2D gamma analysis of sagittal slice at isocenter comparing the study reference plan 
to the plan corresponding to 140 kV and 200 MeV with gamma criteria of 3%/5mm 
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Figure 118. 2D gamma analysis of sagittal slice at isocenter comparing the study reference plan 
to the plan corresponding to 140 kV and 250 MeV with gamma criteria of 3%/5mm 
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